Abstract:The development of inhibitory antibodies to factor VIII or factor IX is the most serious complication of replacement therapy for people with hemophilia. Inhibitors decrease effectiveness of treatment, increasing risk of morbidity including bleeding frequency and arthropathy, and mortality. The current study examined the association between history of inhibitors and physical growth measured by skeletal maturation (bone age, BA) in participants enrolled in the longitudinal Hemophilia Growth and Development Study (HGDS). The HGDS is a population-based multicenter study of children and adolescents enrolled between 1989 and 1990. Participants not skeletally mature (n=306) were included in this investigation. Their mean age was 12, range 7–18 years. Seventy-five percent had severe hemophilia, 19% moderate, and 6% mild. Eighteen percent (n=54) had a history of inhibitors, with maximum lifetime Bethesda titers ranging from 1 to 2048. In general, HGDS participants received on-demand therapy prior to and during study follow-up. Skeletal maturation was determined centrally from x-rays of the hand-wrist according to the Fels method. Readers were masked to the clinical status of participants. Growth delay was defined as chronological age (age) minus BA and modelled using a longitudinal mixed effects polynomial model including age, race, HIV and inhibitor status, and their interactions. P-values were adjusted for multiple comparisons using Scheffe's method. At every year evaluated (10 through 16), growth delay was greater among HIV-negative subjects with a history of inhibitors compared to HIV-negative subjects without inhibitors (p-values ranged from 0.042 to 0.12). The greatest differences, 9 to 10 months, were observed during the period of expected maximum growth velocity, 12 through 14 years of age (all p<0.05). At ages 15 and 16, subjects with inhibitors lagged approximately 9 months behind those without inhibitors in their skeletal maturation (p=0.067 and 0.12). The predicted BA of HIV-negative adolescents without inhibitors was quite similar to age during this period. At 12, 13, 14, 15 and 16 years, they were 11.9, 13.1, 14.3, 15.4, and 16.4 respectively. Previous investigations from the HGDS have reported delays in skeletal maturation associated with HIV. In this study, delays were greater among HIV-positive subjects with an inhibitor compared to HIV-positive subjects without an inhibitor at every age, but perhaps due to intervening effects of HIV, the differences were generally small (1 to 2 months) and not statistically significant. In conclusion, the differences in bone age relative to chronological age between the HIV-negative groups suggest that a history of inhibitors is associated with delays in onset of puberty. Further investigation of this association and other growth parameters is a priority. If confirmed, the observation has important clinical, epidemiologic and therapeutic implications for the children and adolescents most severely impacted by hemophilia.

Longitudinal Neurological Follow-Up of a Group of HIV-seropositive and HIV-seronegative Hemophiliacs: Results from the Hemophilia Growth and Development Study.

Effect of age on human immunodeficiency virus type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders. Transfusion Safety Study Group

Delays in Maturation among Adolescents with Hemophilia and a History of Inhibitors.

Neurocognitive Dysfunction With Neuronal Injury in People With HIV on Long-Duration Antiretroviral Therapy

Association Between a History of Inhibitors and Delays in Skeletal Maturation in Adolescents with Hemophilia.

Neurocognitive Development in Perinatally Human Immunodeficiency Virus-infected Adolescents on Long-term Treatment, Compared to Healthy Matched Controls: A Longitudinal Study

The Effect of Plasma Human Immunodeficiency Virus RNA and CD41 T Lymphocytes on Growth Measurements of Hemophilic Boys and Adolescents

The Effect of Plasma Human Immunodeficiency Virus RNA and CD4+ T Lymphocytes on Growth Measurements of Hemophilic Boys and Adolescents

HIV-associated Dementia: New Insights into Disease Pathogenesis and Therapeutic Interventions.

Effects of perinatal HIV-infection on the cortical thickness and subcortical gray matter volumes in young adulthood

Neurocognitive Functioning is Impaired in Perinatally HIV-Infected Youth

[Clinical Impacts of Highly Active Antiretroviral Therapy on Patients of Hemophilia Combined with Acquired Immunodeficiency Syndrome: 6-Year Follow-Up of 39 Cases].

A Longitudinal Analysis of Cerebral Blood Flow in Perinatally HIV Infected Adolescents as Compared to Matched Healthy Controls

African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus

Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers

Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion

The Association Between Serum Mature and Precursor Brain-Derived Neurotrophic Factor and Neurocognitive Function in People With Human Immunodeficiency Virus: A Longitudinal Study

Learning and memory function in young people with and without perinatal HIV in England

Four years clinical analysis of 50 cases of hemophilia patients co-infected by AIDS/HCV treated with active antiretroviral therapy

Longitudinal Intra- and Inter-individual variation in T-cell subsets of HIV-infected and uninfected men participating in the LA Multi-Center AIDS Cohort Study

Characterization of the Functional Properties of Env Genes from Longterm Survivors of Human Immunodeficiency Virus Type 1 Infection